收藏切换
Analysis of commercial health insurance mode for chimeric antigen receptor T cell products
收藏切换
Shengxin HUANG1, Jinxi DING1, 2, *, Jiaming LI1, 2, Wei LI1, 2
World Clinical Drug | 2022, 43(4) : 359 - 368
Less
收藏切换
World Clinical Drug | 2022, 43(4): 359-368
• Topic •
Analysis of commercial health insurance mode for chimeric antigen receptor T cell products
Full
Shengxin HUANG1, Jinxi DING1, 2, *, Jiaming LI1, 2, Wei LI1, 2
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2022-04-10 doi: 10.13683/j.wph.2022.04.003
Outline
收藏切换

Chimeric antigen receptor T cell (CAR-T) is a novel cancer immunotherapy, but it priced over a million yuan, so it has not been included in National Reimbursement Drug List (NRDL), resulting in its poor affordability. Under the background of multi-level healthcare security system, a small number of commercial health insurance companies in China have first explored the inclusion of CAR-T products in their coverage, which has reduced the burden of patients to a certain extent. The paper selected two mainstream commercial health insurance products, Urban Customized Commercial Health Insurance (UCCHI) and Million Medical Insurance product, as analysis objects. Furthermore, this paper, taking into account international experience and the development needs of Chinese commercial insurance, summarized the current coverage situation of CAR-T products, and proposed to optimize the design of commercial insurance products in four aspects: high premium, high benefit, long term and close connection, in order to provide better coverage for CAR-T products and other high-value innovative drugs with "good efficacy, high cost and uncertain population".

chimeric antigen receptor T cell (CAR-T)  /  commercial health insurance  /  high-value innovative drug
黄晟馨, 丁锦希, 李佳明, 李伟. 嵌合抗原受体T细胞产品商业健康保险模式分析. 世界临床药物, 2022 , 43 (4) : 359 -368 . DOI: 10.13683/j.wph.2022.04.003
Shengxin HUANG, Jinxi DING, Jiaming LI, Wei LI. Analysis of commercial health insurance mode for chimeric antigen receptor T cell products[J]. World Clinical Drug, 2022 , 43 (4) : 359 -368 . DOI: 10.13683/j.wph.2022.04.003
Year 2022 volume 43 Issue 4
14
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.04.003
  • Receive Date:2022-01-26
  • Online Date:2026-11-19
  • Published:2022-04-10
Article Data
Affiliations
History
  • Received:2022-01-26
Funding
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.04.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT